Purpose. To compare survival rates in the elderly with bone versus soft-tissue sarcomas. Methods. Records of 12 men and 8 women aged 70 to 91 (mean, 77) years with bone or soft-tissue sarcomas were retrospectively reviewed. The grade, size, location, and stage of the sarcomas, as well as their surgical margins, treatment modalities, local recurrence, metastasis, and prognosis were recorded. The mean follow-up period was 37 (range, 2-137) months. Their 5-year survival rates were estimated using the Kaplan-Meier method, and compared with 110 younger controls aged 9 to 69 (mean, 45) years during the same period. There was no significant difference between the older patients and younger controls regarding tumour grading (p=0.068, Chi squared test), stage, and pathological diagnosis. Results. Six patients had bone and 14 had soft-tissue sarcomas. Of the 6 bone sarcomas, 3 were malignant fibrous histiocytomas, 2 were osteosarcomas, and one was a chordoma; all were high grade, except for the chordoma. Of the 14 soft-tissue sarcomas, 9 were malignant fibrous histiocytomas, 3 were myxofibrosarcomas, one was a liposarcoma and Bone versus soft-tissue sarcomas in the elderly one an extraskeletal osteosarcoma; all were high grade except for 2 of the myxofibrosarcomas and the liposarcoma. Of the 110 younger controls, 30 had bone and 80 had soft-tissue sarcomas; 44 were low grade and 66 were high grade. The 5-year survival rate was significantly lower in older patients than in younger controls (35% vs 65%, p=0.048). Regarding bone versus soft-tissue sarcomas, the 5-year survival rate was not significantly different among older patients (0% vs 52%, p=0.068) or younger controls (61% vs 66%, p=0.863). The difference was also not significant for older patients versus younger controls with bone sarcomas (0% vs 61%, p=0.284) or soft-tissue sarcomas (52% vs 66%, p=0.368), for older patients with high-versus low-grade sarcomas (17% vs 100%, p=0.314), for older patients with sarcomas located in the limbs versus the trunk (39% vs 38%, p=0.233), as well as for older patients versus younger controls with low-grade sarcomas (100% vs 92%, p=0.512) or high-grade sarcomas (17% vs 46%, p=0.269). Conclusion. Survival rates tend to be lower in older patients with sarcomas, especially when the sarcoma is of bone and high grade.
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INTRODUCTION
The incidence of bone and soft-tissue sarcomas in older patients tends to increase as life expectancy becomes longer. The World Health Organization defines the elderly as persons aged 65 years and over. In a public awareness survey in Japan, 46% of respondents considered the elderly as persons aged 70 years and over. 1 We compared survival rates of the elderly with bone versus soft-tissue sarcomas.
MATERIALS AND METHODS
Between 1997 and 2006, records of 12 men and 8 women aged 70 to 91 (mean, 77) years with bone or soft-tissue sarcomas were retrospectively reviewed. The grade, size, location, and stage of the sarcomas, as well as their surgical margins (according to Enneking criteria), treatment modalities (limb salvage, amputation, chemotherapy, radiotherapy), local recurrence, metastasis, and prognosis were recorded. The mean follow-up period was 37 (range, 2-137) months. Their 5-year survival rates were estimated using the Kaplan-Meier method, and compared with 110 younger controls aged 9 to 69 (mean, 45) years during the same period using the log rank test.
RESULTS
Six patients had bone and 14 had soft-tissue sarcomas. Of the 6 bone sarcomas, 3 were malignant fibrous histiocytomas, 2 were osteosarcomas, and one was a chordoma; all were high grade except for the chordoma. Of the 14 soft-tissue sarcomas, 9 were malignant fibrous histiocytomas, 3 were myxofibrosarcomas, one was a liposarcoma and one an extraskeletal osteosarcoma; all were high grade except for 2 of the myxofibrosarcomas and one liposarcoma ( Table 1) . These sarcomas were located in the upper limbs (n=2), lower limbs (n=10), and trunk (n=8). Of the 110 younger controls, 30 had bone and 80 had soft-tissue sarcomas; 44 were low grade and 66 high grade. There was no significant difference between the older patients and younger controls regarding tumour grading (p=0.068, Chi squared test), stage, and pathological diagnosis.
According to the criteria of the International Union Against Cancer, the sarcomas in older patients were classified into stages I (n=4), II (n=7), and III (n=9). 14 of the patients underwent a resection (12 were wide, one marginal, and one entailed belowknee amputation); 4 of them also had radiotherapy.
No surgery was performed for the remaining 6 patients because of the difficult tumour location (retroperitoneal and pelvic), being deemed not physically fit enough to withstand the operation, or refusal to have surgery. They were treated with extra-beam radiotherapy (n=2), radiotherapy and chemotherapy (n=1), heavy-particle radiotherapy (n=1), heavy-particle radiotherapy and chemotherapy (n=1), or palliation (n=1). Chemotherapy was opted for when the sarcoma was deep-seated, larger than 5 cm, high-grade, and the patient was deemed fit enough. The dosage of chemotherapy was decreased to 70% of normal, and the response rate was expected to be only 33%. 2 No fatal side-effect was noted. Two patients had local recurrence. One had no evidence of disease after a second resection of the well-differentiated liposarcoma in the thigh 62 months after the first marginal resection. Another is alive with the disease after heavy-particle radiotherapy for the chordoma arising from the sacrum. All 8 patients who remained disease-free had soft-tissue sarcomas.
The 5-year survival rate was significantly lower in older patients than in younger controls (35% vs 65%, p=0.048, Fig. 1 ). Regarding bone versus soft-tissue sarcomas, the 5-year survival rate was not significantly different among older patients (0% vs 52%, p=0.068, Fig. 2 ) or younger controls (61% vs 66%, p=0.863). The difference was also not significant for older patients versus younger controls with bone sarcomas (0% vs 61%, p=0.284, Fig. 3 ) or soft-tissue sarcomas (52% vs 66%, p=0.368, Fig. 4) , for older patients with highversus low-grade sarcomas (17% vs 100%, p=0.314, Fig. 5 ), for older patients with sarcomas located in the limbs versus the trunk (39% vs 38%, p=0.233, Fig. 6 ), for older patients versus younger controls with lowgrade sarcomas (100% vs 92%, p=0.512, Fig. 7 ) or highgrade sarcomas (17% vs 46%, p=0.269, Fig. 8 ).
DISCUSSION
According to the Musculoskeletal Tumor Committee of the Japanese Orthopaedic Association, the incidence of bone sarcomas peaks in the 2nd and 8th decade of life, whereas the incidence of soft-tissue sarcomas peaks in the 7th decade of life (Table 2) . 3, 4 Of 43 patients aged ≥65 years with high-grade bone osteosarcomas, 14 had metastatsis and 13 had an osteosarcoma related to Paget's disease, 2 which accounts for 3.3% of all osteosarcomas.
5 69% of osteosarcomas related to Paget's disease occur in patients older than 60 years, 5 but such an incidence was rare in Japanese patients; none of 12 patients with secondary osteosarcomas was related to Paget's disease, 6 and indeed none of our patients had a secondary bone sarcoma.
An effective chemotherapy regimen for most soft-tissue sarcomas has not been established, except for extra-skeletal Ewing's sarcomas/primitive neuroectodermal tumours and rhabdomyosarcomas. 7, 8 Wide resections can be avoided if the local control rate is high following high-dose irradiation.
In patients (aged ≥65 years) with low-and high- 
